GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment…Read More
GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson’s DiseaseRead More
GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson’s Disease Cannabinoid Formulations and Begins Mechanism…Read More
GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based…Read More
GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of DirectorsRead More
